Related Experiment Video
Updated: Jul 11, 2026
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer
Ahmed M Salem1, Samir F Zohny, Manal M Abd El-Wahab
1Faculty of Science, Biochemistry Department, Ain Shams University, 11566, Abbassia, Cairo, Egypt.
Objectives:
Assessment of the diagnostic value of serum CEA, CA 15.3, osteocalcin (OC) and beta-CrossLaps (beta-CTX) in the detection of metastatic breast cancer.
Design And Methods:
This study included 47 patients with breast cancer (20 non-metastatic breast cancer, 11 bone metastasis, 11 soft tissue metastasis, 5 bone plus soft tissue metastasis), 10 patients with benign breast lesions and 13 healthy volunteers. CEA and CA 15.3 were determined using microparticle enzyme immunoassay; while OC and beta-CTX were measured by electrochemiluminescence immunoassay.
Results:
CEA, CA 15.3, OC and beta-CTX median levels were higher in breast cancer patients compared to controls (p=0.006, 0.001, 0.004 and 0.038, respectively). Increased levels of OC and beta-CTX were demonstrated in bone metastatic patients compared to non-metastatic or soft tissue metastatic patients (p=0.000).
Conclusions:
Combined use of OC and beta-CTX could be useful in early detection of bone metastatic breast cancer which might improve the outcome of the disease.
